424 related articles for article (PubMed ID: 26923330)
21. Cyclin-dependent protein kinase inhibitors including palbociclib as anticancer drugs.
Roskoski R
Pharmacol Res; 2016 May; 107():249-275. PubMed ID: 26995305
[TBL] [Abstract][Full Text] [Related]
22. CDK 4/6 inhibitor palbociclib (PD0332991) in Rb+ advanced breast cancer: phase II activity, safety, and predictive biomarker assessment.
DeMichele A; Clark AS; Tan KS; Heitjan DF; Gramlich K; Gallagher M; Lal P; Feldman M; Zhang P; Colameco C; Lewis D; Langer M; Goodman N; Domchek S; Gogineni K; Rosen M; Fox K; O'Dwyer P
Clin Cancer Res; 2015 Mar; 21(5):995-1001. PubMed ID: 25501126
[TBL] [Abstract][Full Text] [Related]
23. Combining CDK4/6 inhibition with taxanes enhances anti-tumor efficacy by sustained impairment of pRB-E2F pathways in squamous cell lung cancer.
Cao J; Zhu Z; Wang H; Nichols TC; Lui GYL; Deng S; Rejto PA; VanArsdale T; Hardwick JS; Weinrich SL; Wei P
Oncogene; 2019 May; 38(21):4125-4141. PubMed ID: 30700828
[TBL] [Abstract][Full Text] [Related]
24. Modulation of Rb phosphorylation and antiproliferative response to palbociclib: the preoperative-palbociclib (POP) randomized clinical trial.
Arnedos M; Bayar MA; Cheaib B; Scott V; Bouakka I; Valent A; Adam J; Leroux-Kozal V; Marty V; Rapinat A; Mazouni C; Sarfati B; Bieche I; Balleyguier C; Gentien D; Delaloge S; Lacroix-Triki M; Michiels S; Andre F
Ann Oncol; 2018 Aug; 29(8):1755-1762. PubMed ID: 29893769
[TBL] [Abstract][Full Text] [Related]
25. RABL6A Is an Essential Driver of MPNSTs that Negatively Regulates the RB1 Pathway and Sensitizes Tumor Cells to CDK4/6 Inhibitors.
Kohlmeyer JL; Kaemmer CA; Pulliam C; Maharjan CK; Samayoa AM; Major HJ; Cornick KE; Knepper-Adrian V; Khanna R; Sieren JC; Leidinger MR; Meyerholz DK; Zamba KD; Weimer JM; Dodd RD; Darbro BW; Tanas MR; Quelle DE
Clin Cancer Res; 2020 Jun; 26(12):2997-3011. PubMed ID: 32086342
[TBL] [Abstract][Full Text] [Related]
26. Palbociclib (PD 0332991) : targeting the cell cycle machinery in breast cancer.
Rocca A; Farolfi A; Bravaccini S; Schirone A; Amadori D
Expert Opin Pharmacother; 2014 Feb; 15(3):407-20. PubMed ID: 24369047
[TBL] [Abstract][Full Text] [Related]
27. CDK4/6 and autophagy inhibitors synergistically induce senescence in Rb positive cytoplasmic cyclin E negative cancers.
Vijayaraghavan S; Karakas C; Doostan I; Chen X; Bui T; Yi M; Raghavendra AS; Zhao Y; Bashour SI; Ibrahim NK; Karuturi M; Wang J; Winkler JD; Amaravadi RK; Hunt KK; Tripathy D; Keyomarsi K
Nat Commun; 2017 Jun; 8():15916. PubMed ID: 28653662
[TBL] [Abstract][Full Text] [Related]
28. The transcriptome of CDK4/6 inhibition.
Knudsen ES; Witkiewicz AK
Aging (Albany NY); 2017 Aug; 9(8):1859-1860. PubMed ID: 28860413
[No Abstract] [Full Text] [Related]
29. Cyclin-Dependent Kinase 4/6 Inhibitors for the Treatment of Breast Cancer: A Review of Preclinical and Clinical Data.
Vidula N; Rugo HS
Clin Breast Cancer; 2016 Feb; 16(1):8-17. PubMed ID: 26303211
[TBL] [Abstract][Full Text] [Related]
30. Cyclin-dependent kinase 4/6 inhibitors in hormone receptor-positive early breast cancer: preliminary results and ongoing studies.
Kwapisz D
Breast Cancer; 2018 Sep; 25(5):506-516. PubMed ID: 29700711
[TBL] [Abstract][Full Text] [Related]
31. Modification of the DNA damage response by therapeutic CDK4/6 inhibition.
Dean JL; McClendon AK; Knudsen ES
J Biol Chem; 2012 Aug; 287(34):29075-87. PubMed ID: 22733811
[TBL] [Abstract][Full Text] [Related]
32. Pan-cancer molecular analysis of the RB tumor suppressor pathway.
Knudsen ES; Nambiar R; Rosario SR; Smiraglia DJ; Goodrich DW; Witkiewicz AK
Commun Biol; 2020 Apr; 3(1):158. PubMed ID: 32242058
[TBL] [Abstract][Full Text] [Related]
33. Preclinical development of G1T38: A novel, potent and selective inhibitor of cyclin dependent kinases 4/6 for use as an oral antineoplastic in patients with CDK4/6 sensitive tumors.
Bisi JE; Sorrentino JA; Jordan JL; Darr DD; Roberts PJ; Tavares FX; Strum JC
Oncotarget; 2017 Jun; 8(26):42343-42358. PubMed ID: 28418845
[TBL] [Abstract][Full Text] [Related]
34. CDK inhibitors as potential breast cancer therapeutics: new evidence for enhanced efficacy in ER+ disease.
Sutherland RL; Musgrove EA
Breast Cancer Res; 2009; 11(6):112. PubMed ID: 20067604
[TBL] [Abstract][Full Text] [Related]
35. Next-generation sequencing reveals mutations in RB1, CDK4 and TP53 that may promote chemo-resistance to palbociclib in ovarian cancer.
El Shamieh S; Saleh F; Assaad S; Farhat F
Drug Metab Pers Ther; 2019 May; 34(2):. PubMed ID: 31145688
[TBL] [Abstract][Full Text] [Related]
36. Different inhibitors for the same target in metastatic luminal breast cancer: is there any difference?
El Rassy E; Bakouny Z; Assi T; Kattan J
Future Oncol; 2018 Apr; 14(9):891-895. PubMed ID: 29527939
[TBL] [Abstract][Full Text] [Related]
37. Clinical development of CDK4/6 inhibitor for breast cancer.
Iwata H
Breast Cancer; 2018 Jul; 25(4):402-406. PubMed ID: 29392622
[TBL] [Abstract][Full Text] [Related]
38. CDK4/6 inhibitors in breast cancer.
Dukelow T; Kishan D; Khasraw M; Murphy CG
Anticancer Drugs; 2015 Sep; 26(8):797-806. PubMed ID: 26053278
[TBL] [Abstract][Full Text] [Related]
39. [Cell cycle inhibitors in endocrine receptor positive breast cancer].
Sablin MP; Ricci F; Loirat D; Jobard A; Basse C; Romano E; Le Tourneau C; Dieras V
Bull Cancer; 2017 Feb; 104(2):114-122. PubMed ID: 28126188
[TBL] [Abstract][Full Text] [Related]
40. Targeting CDK4/6 in patients with cancer.
Hamilton E; Infante JR
Cancer Treat Rev; 2016 Apr; 45():129-38. PubMed ID: 27017286
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
